Ms. Jung Eun Choi is a partner at Shin & Kim whose practice focuses on healthcare, retail and consumer products and mergers and acquisitions.

Ms. Choi provides practical and prompt advice on day-to-day legal matters based on her extensive experience in M&A and operations. She advises pharmaceutical companies, medical device companies, and food and cosmetics companies on ongoing legal matters, and also advises healthcare industry clients on M&A transactions, including the sale of stakes, capital raising, and business transfers.

Advisory

• Advised a cosmetics company on responses to counterfeit and copycat products, including the filing of criminal complaints.
• Advised a cosmetics company on a broad range of commercial and regulatory matters, including the drafting, review, and negotiation of various business agreements such as ODM/OEM and distribution agreements, as well as regulatory compliance relating to licensing, labeling and advertising, hazardous substances, packaging materials, and the handling of chemical substances.
• Advised pharmaceutical companies, new drug development companies, medical device manufacturers, and food and cosmetics companies on the drafting, review, and negotiation of a wide range of commercial agreements, including co-promotion and supply agreements, joint development agreements, manufacturing services agreements, clinical trial agreements, PMS agreements, and license agreements.
• Advised a multinational pharmaceutical company on disputes arising from the performance of co-promotion and supply agreements.
• Advised pharmaceutical companies on a wide range of licensing and dispute matters, including internal whistleblowing related to rebates, reimbursement reductions, and disputes relating to clinical trial agreements, as well as matters relating to investment transactions and corporate restructuring.
• Advised hospitals and clinics on business transfers, business restructuring, medical malpractice disputes, and issues relating to improper or fraudulent reimbursement claims.
• Advised on the establishment and operation of non-profit entities, including medical corporations and foundations.
• Participated in a research project on improvements to the decentralized clinical trial system (2023 Smart Clinical Trial New Technology Development Project, Phase 1: Research on the development and dissemination of new technologies, including remote monitoring, to establish a nationwide foundation for decentralized clinical trials).

M&A

• Advised on Olive Young’s attempted acquisition of Skinfood.
• Advised on the acquisition of a botulinum toxin manufacturer.
• Advised STIC Investment on its acquisition of exchangeable bonds issued by CHA Biotech.
• Advised Orion on the acquisition of LigaChem Biosciences
• Advised on the sale of a controlling stake in a listed new drug development company.
• Advised a domestic strategic investor on a proposed investment in Alteogen (transaction did not proceed).
• Advised SK Telecom on the acquisition of 3D oral scanner company Medit
• Advised OCI on its acquisition of shares in Bukwang Pharmaceutical.
• Advised Dong-A ST on its acquisition of AbTis.
• Advised Kakao on its investment in Humanscape.
• Advised Helios PEF on its acquisition of shares in ISC, a semiconductor test socket manufacturer, and on the subsequent sale of such shares to SKC.
• Advised SK E&S and NHN on their acquisition of existing and newly issued shares in Parking Cloud.
• Advised Hyundai HCN on the spin-off of its cable TV business division and the subsequent sale of shares.
• Advised SKC on the sale of shares to Kuwait’s PIC and Hahn & Company following the spin-off of its chemical and film business divisions.
• Advised CJ CheilJedang on its acquisition of shares in Schwan’s, a U.S. frozen food company.
• Advised Wooriwa on the acquisition of the animal feed business of Daesan & Company and the acquisition of assets relating to the animal feed business of ANF Pet in the United States.
• Advised F&F on the human spin-off of its fashion business.